A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment

Table 7 Frequency and grade of adverse events of the 12 patients

Grade^a	I	II	III	IV	V
Adverse event	I	II	III	IV	V
Local pain	3/12^b	2/12
Local swelling		1/12
Fever	5/12	2/12
Skin rash/itching/skin desquamation	3/12	2/12
Myalgia	1/12
Bilirubin	4/12	1/12	2/12	1/12
GPT	9/12	2/12
GOT	9/12	2/12	1/12
Hemorrhage (UGI^c)		1/12
Diarrhea/Mucocitis	3/12	1/12	2/12
Creatinine	1/12	1/12
Allergy	1/12	1/12
Anemia	1/12	1/12
Short of breath	2/12
Sweating	1/12
Chillness	1/12
Leg edema	1/12

^aAdverse event was determined using CTCAE version 4.0
^b“3/12” indicates that 3 of 12 patients had at least one episode of a particular adverse event
^cUGI indicates upper gastrointestinal

ISSN: 1423-0127